Discontinuation of anti-TNF-α therapy in a Chinese cohort of patients with rheumatoid arthritis

Clinical Rheumatology

Volumn 31, Issue 11, 2012, Pages 1549-1557

  Yang, Cheng Tao ^a   Kuo, Chang Fu ^a   Luo, Shue Fen ^a   Yu, Kuang Hui ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Adverse event; Infection; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ETANERCEPT;

ACUTE APPENDICITIS; ACUTE LIVER FAILURE; ACUTE PYELONEPHRITIS; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BILIARY TRACT INFECTION; CELLULITIS; CHINESE; COHORT ANALYSIS; DEMYELINATING DISEASE; DRUG WITHDRAWAL; DUODENUM ULCER; FEMALE; HEPATITIS; HERPES SIMPLEX; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENINGITIS; NEUROPATHY; PANCYTOPENIA; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SEPSIS; STAPHYLOCOCCUS INFECTION; STOMACH PERFORATION; TRANSIENT GLOBAL AMNESIA; TREATMENT DURATION; TUBERCULOSIS; ULCER PERFORATION; URINARY TRACT INFECTION; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; ODDS RATIO; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; RHEUMATOLOGY; TAIWAN; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872191663     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-012-2047-8     Document Type: Article

References (35)

1. McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205-2219
2. Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376:1094-1108
3. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54:2368-2376
4. Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F et al (2009) TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 1173:837-846
5. Levälampi T, Korpela M, Vuolteenaho K, Moilanen E (2008) Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment. Rheumatol Int 28:261-269
6. Levälampi T, Korpela M, Vuolteenaho K, Moilanen E (2008) Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment. Scand J Rheumatol 37:6-12
7. Konttinen L, Honkanen V, Uotila T, Pöllänen J, Waahtera M, Romu M et al (2006) Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events. Rheumatol Int 26:916-922
8. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932-1939
9. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patientswith rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253-259
10. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA et al (2003) Adalimumab, a fully human antitumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35-45
11. Chen DY, Chou SJ, Hsieh TY, Chen YH, Chen HH, Hsieh CWet al (2009) Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. J Formos Med Assoc 108:310-319
12. Chou CT (2006) The clinical application of etanercept in Chinese patients with rheumatic diseases. Mod Rheumatol 16:206-213
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
14. Tanaka Y, Takeuchi T, Mimori T, Saito K, NawataM, Kameda H et al (2010) Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 69:1286-1291
15. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL (2008) Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 59:800-806
16. Tam LS, Leung CC, Ying SK, Lee GK, Yim CW, Leung YY et al (2010) Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong - the role of TNF blockers in an area of high tuberculosis burden. Clin Exp Rheumatol 28:679-685
17. Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A (2008) Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 9:52
18. Blom M, Kievit W, Fransen J, Kuper IH, den Broeder AA, De Gendt CM et al (2009) The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol 36:2171-2177
19. Dahl SL, Samuelson CO, Williams HJ, Ward JR, Karg M (1990) Second-line antirheumatic drugs in the elderly with rheumatoid arthritis: a post hoc analysis of three controlled trials. Pharmacotherapy 10:79-84
20. Radovits BJ, KievitW, Fransen J, van de Laar MA, Jansen TL, van Riel PL et al (2009) Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 68:1470-1473
21. van Schaardenburg D, Breedveld FC (1994) Elderly-onset rheumatoid arthritis. Semin Arthritis Rheum 23:367-378
22. Yung RL (2000) Changes in immune function with age. Rheum Dis Clin North Am 26:455-473
23. Weiskopf D, Weinberger B, Grubeck-Loebenstein B (2009) The aging of the immune system. Transpl Int 22:1041-1050
24. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098-1104
25. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M et al (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60:1884-1894
26. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R et al (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3:148-155
27. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C et al (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301:737-744
28. Ramos-Casals M, Brito-Zerón P, Soto MJ, Cuadrado MJ, Khamashta MA (2008) Autoimmune diseases induced by TNFtargeted therapies. Best Pract Res Clin Rheumatol 22:847-861
29. Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J et al (2011) Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol 38:1273-1281
30. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A et al (2009) Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 61:560-568
31. Levalampi T, Korpela M, Vuolteenaho K, Moilanen E (2008) Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment. Rheumatol Int 28:261-269
32. Patkar NM, Teng GG, Curtis JR, Saag KG (2008) Association of infections and tuberculosis with antitumor necrosis factor alpha therapy. Curr Opin Rheumatol 20:320-326
33. Hsueh PR, Liu YC, So J, Liu CY, Yang PC, Luh KT (2006) Mycobacterium tuberculosis in Taiwan. J Infect 52:77-85
34. Ornstein MH, Sperber K (1996) The anti-inflammatory and antiviral effects of hydroxychloroquine in two patients with acquired immunodeficiency syndrome and active inflammatory arthritis. Arthritis Rheum 39:157-161
35. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, British Society for Rheumatology Biologics Register (2007) Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 56:2896-2904